Shanghai Fosun Pharmaceutical (02196): Sodium Thiosulfate Injection Approved for Registration

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary Chongqing Kailin Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration application of Sodium Thiosulfate Injection, which is intended for cyanide poisoning and can also be used for arsenic, mercury, lead, bismuth, iodine poisoning. This drug is a chemical product independently developed by the group (including the company and its subsidiaries/units). As of February 2026, the group has accumulated research and development investment of approximately RMB 1.87 million (unaudited) for this drug. According to the latest data from IQVIA CHPA, in 2025, the sales of Sodium Thiosulfate formulations in China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 431 million.